The cancellation of 63,650 Orion Corporation A shares and 59,900 B shares has today on 25 June 2020 been entered in the Trade Register. The cancellation reduces the number of Orion A and B shares with the corresponding amounts but has no effect on the share capital. The Board of Directors of Orion Corporation decided on the share cancellation on 15 June 2020.
The total number of shares in Orion Corporation after the share cancellation is 141 134 278, of which 35,443,475 are A shares and 105,690,803 are B shares. The total number of votes of the company's shares is 814,560,303 and Orion holds 671,082 B shares as treasury shares.
| Timo Lappalainen|
President and CEO
| Olli Huotari|
SVP, Corporate Functions
Tuukka Hirvonen, Investor Relations
tel. +358 010 426 2721
Orionintie 1A, FI-02200 Espoo, Finland
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology, Finnish heritage rare diseases and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2019 amounted to EUR 1,051 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.